ArticleBlood advances2019
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Amy K Keating et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
39 papers cite it
this papertrialcites it